Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit

Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. Learn how you can help make a difference by joining the All of Us Research Program.

Displaying 41 - 50 of 267

Combination Post-transplant Consolidation Therapy with Isatuximab, Lenalidomide, Dexamethasone (IsaRD) in Multiple Myeloma Patients with Persistent Marrow Minimal Residual Disease (Elimination of MRD After Transplant; E-MAT)

The purpose of this study is to test the safety and effectiveness of the new study drug combination of Isatuximab, Lenalidomide, and Dexamethasone for the treatment of multiple myeloma in patients with Persistent Marrow Minimal Residual Disease.
Protocol No